| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 261.432 | 250.933 | 277.906 | 285.508 | 296.537 | 337.046 | 322.084 | 368.621 | 411.417 | 430.743 |
| Total Income - EUR | 262.574 | 261.780 | 286.829 | 289.933 | 300.800 | 341.538 | 328.636 | 373.890 | 417.189 | 437.751 |
| Total Expenses - EUR | 248.836 | 241.246 | 262.127 | 268.965 | 283.775 | 313.650 | 305.625 | 355.490 | 404.694 | 416.953 |
| Gross Profit/Loss - EUR | 13.738 | 20.534 | 24.702 | 20.969 | 17.025 | 27.888 | 23.011 | 18.400 | 12.495 | 20.799 |
| Net Profit/Loss - EUR | 11.407 | 17.170 | 21.670 | 18.069 | 14.015 | 24.728 | 20.119 | 14.736 | 9.002 | 7.929 |
| Employees | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Ginco Pharm S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 22.605 | 22.375 | 21.996 | 21.592 | 21.174 | 21.289 | 20.608 | 20.463 | 11.034 | 4.841 |
| Current Assets | 79.670 | 59.607 | 75.407 | 67.242 | 84.733 | 76.161 | 88.055 | 103.865 | 98.515 | 105.329 |
| Inventories | 38.296 | 36.115 | 35.026 | 35.274 | 38.849 | 35.630 | 42.825 | 44.856 | 49.259 | 63.290 |
| Receivables | 26.059 | 7.498 | 30.959 | 28.488 | 43.468 | 36.989 | 33.497 | 50.464 | 34.500 | 24.538 |
| Cash | 15.315 | 15.994 | 9.421 | 3.480 | 2.416 | 3.542 | 11.733 | 8.545 | 14.755 | 17.500 |
| Shareholders Funds | 25.638 | 17.278 | 22.019 | 24.642 | 25.118 | 27.832 | 27.158 | 14.785 | 10.643 | 8.505 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 66.317 | 64.704 | 75.384 | 64.193 | 80.790 | 69.619 | 81.505 | 109.543 | 98.906 | 101.665 |
| Income in Advance | 10.320 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4773 - 4773" | |||||||||
| CAEN Financial Year |
4773
|
|||||||||
Comments - Ginco Pharm S.r.l.